Publications

Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn

Quoted, Pink Sheet Citeline Regulatory

Chad Landmon, Hatch-Waxman & Biologics Chair, explains why the Lilly lawsuit exemplifies the type of cases expected in the post-Chevron world. 

(subscription required)